Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
(2024) 16:e55195
Landmark studies such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown significant reductions in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
What regulatory standards were followed in Phase 1 trials
Table 1 Summary of the main studies with SGLT-2i
US$ 20.65
US$ 22.95
US$ 23.53
US$ 28.58
